Bavarian Nordic Presents Combination Immunotherapy Data of PROSTVAC plus Ipilimumab at the AACR Annual Meeting 2014
KVISTGAARD, Denmark, April 7, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY)
announced today that updated data from an NCI sponsored combination study of
Bavarian Nordic's active immunotherapy candidate PROSTVAC and ipilimumab will be
presented at the American Association for Cancer Research (AACR) Annual Meeting
in San Diego on Wednesday, April 9, 2014. The data highlights the potential
synergy of combining PROSTVAC with an immune checkpoint inhibitor.
Promising results showing clinical evidence from this phase 1 trial combining
PROSTVAC plus ipilimumab were previously published in The Lancet Oncology. The
reported median overall survival was 34.4 months in men with metastatic prostate
cancer, and the combination therapy was well-tolerated. The presentation at the
AACR conference will show hypothesis-generating data correlating immune outcomes
with overall survival. These data provide rationale for prospectively evaluating
these potential immune correlates of clinical benefit from combining PROSTVAC
and immune checkpoint blockade in follow-on clinical studies.
The senior author for the presentation as a poster is Jeffrey Schlom, Ph.D.,
Chief, Laboratory of Tumor Immunology and Biology, National Cancer Institute,
NIH. The presentation will take place on Wednesday, April 9, 2014 from 8:00 AM
-12:00 PM PDT. An abstract entitled: "A combination trial of vaccine plus
ipilimumab in metastatic castration-resistant prostate cancer patients: Immune
correlates" is available online at http://bit.ly/1frHjxK.
James B. Breitmeyer, President of the Cancer Immunotherapy Division of Bavarian
Nordic, said: "We are excited to continue exploration of the potential synergy
in clinical response from combination therapy with PROSTVAC and immune
checkpoint inhibitors, including ipilimumab, as well as a number of other
Chairman of the Board
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and
manufacturing novel cancer immunotherapies and vaccines for infectious diseases.
Lead product candidates are PROSTVACÂ®, an immunotherapy product candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3
clinical trial and IMVAMUNEÂ®, a non-replicating smallpox vaccine candidate in
Phase 3 development, which is being developed and supplied for emergency use to
the U.S. Strategic National Stockpile under a contract with the U.S. Government.
The vaccine is approved in Canada under the trade name IMVAMUNE and in the
European Union under the trade name IMVANEXÂ®.
Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol
BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level
1 ADR program listed in the US (OTC) under the symbol BVNRY.
For more information, visit www.bavarian-nordic.com.
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via GlobeNewswire